Finance

Lists
Why is TNXP down 3,69%?
Dive Deeper
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
6,40 $
-3,69%
(-0,24) 1D
13 հոկ, 13:29:09 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Open
6,61 $
High
6,68 $
Low
6,30 $
Mkt. cap
109,68 մլն
Avg. vol.
610,54 հզր
Volume
704,69 հզր
52-wk high
20,69 $
52-wk low
6,30 $
EPS
-12,92 $
Beta
1,78
Shares outstanding
17,15 մլն
No. of employees
142
Open
6,61 $
High
6,68 $
Low
6,30 $
Mkt. cap
109,68 մլն
Avg. vol.
610,54 հզր
Volume
704,69 հզր
52-wk high
20,69 $
52-wk low
6,30 $
EPS
-12,92 $
Beta
1,78
Shares outstanding
17,15 մլն
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersԲերքլի Հեյթս, Նյու Ջերսի, Միացյալ Նահանգներ
Sector-
Analyst ratings
Based on 3 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current 6,40 $
65,00 $ (+916,42%)
Average
38,00 $ (+494,21%)
Lowest
22,00 $ (+244,02%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Reiterated
65,00 $
+916,4%
09/28/2026
Stacy Ku
TD Cowen
Buy
Maintained
22,00 $
+244%
08/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
27,00 $
+322,2%
08/10/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
37,00 $
+478,6%
03/16/2026
Last report
10 օգս, 2026 թ.
Fiscal period
Q2 2026
-2,47 $ / -2,62 $
+5,58%beat
Revenue / Est. (USD)
13,54 մլն / 7,72 մլն
+75,38%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
3,29 մլն
5,39 մլն
6,88 մլն
13,54 մլն
Cost of goods sold
1,37 մլն
1,06 մլն
1,58 մլն
703,00 հզր
Cost of revenue
1,37 մլն
1,06 մլն
1,58 մլն
703,00 հզր
Research and development expenses
9,29 մլն
16,94 մլն
18,21 մլն
19,42 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25,70 մլն
35,68 մլն
28,62 մլն
35,96 մլն
Operating expense
34,99 մլն
52,62 մլն
46,84 մլն
55,38 մլն
Total operating expenses
36,36 մլն
53,68 մլն
48,42 մլն
56,08 մլն
Operating income
-33,07 մլն
-48,29 մլն
-41,54 մլն
-42,54 մլն
Other non operating income
-174,00 հզր
32,00 հզր
-3,00 հզր
551,00 հզր
EBT including unusual items
-32,01 մլն
-46,91 մլն
-40,19 մլն
-40,55 մլն
EBT excluding unusual items
-32,01 մլն
-46,91 մլն
-40,19 մլն
-40,55 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32,01 մլն
-46,91 մլն
-40,19 մլն
-40,55 մլն
Net profit margin
-972,95%
-870,32%
-584,38%
-299,41%
Earnings per share
-3,70
-3,98
-2,93
-2,47
Interest and investment income
1,23 մլն
1,34 մլն
1,35 մլն
1,43 մլն
Interest expense
-
-
-
-
Net interest expenses
1,23 մլն
1,34 մլն
1,35 մլն
1,43 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-32,61 մլն
-47,80 մլն
-40,98 մլն
-41,92 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps